Woodlands Company leading a program to Prevent and Treat Ebola with DNA-based Therapies
Inovio will support expedited development and scale-up of multiple vaccine candidates to treat Ebola through a DARPA-funded collaboration.
Congressman Brady visited Inovio’s VGXI manufacturing facility in The Woodlands, TX and took a tour of the production plant and provide a statement on the impact of this work and the DNA-based therapeutics being produced at VGXI. Leadership from Inovio Pharmaceuticals and GeneOne Life Sciences will also be present to provide a brief overview of the collaboration and the scope of the DARPA funded project.
How these therapies are different from many other Ebola vaccines in development:
- The vaccine contains DNA only – no virus particles or proteins will be manufactured
- The vaccine can be used to treat to patients who have already been exposed to the virus
- DNA vaccine production can be scaled-up very rapidly in case of an outbreak